Atopic Dermatitis: Striving for Reliable Biomarkers
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a highly heterogeneous inflammatory disease regarding both its pathophysiology and clinical manifestations. However, it is treated according to the “one-size-fits-all” approach, which may restrict response to treatment. Thus, there is an unmet need for the stratification of patients with AD into distinct endotypes and clinical phenotypes based on biomarkers that will contribute to the development of precision medicine in AD. The development of reliable biomarkers that may distinguish which patients with AD are most likely to benefit from specific targeted therapies is a complex procedure and to date none of the identified candidate biomarkers for AD has been validated for use in routine clinical practice. Reliable biomarkers in AD are expected to improve diagnosis, evaluate disease severity, predict the course of disease, the development of comorbidities, or the therapeutic response, resulting in effective and personalized treatment of AD. Among the studied AD potential biomarkers, thymus and activation-regulated chemokine/C-C motif ligand 17 (TARC/CCL17) has the greatest evidence-based support for becoming a reliable biomarker in AD correlated with disease severity in both children and adults. In this review, we present the most prominent candidate biomarkers in AD and their suggested use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
Simpson, E. L., Chalmers, J. R., Hanifin, J. M., Thomas, K. S., Cork, M. J., McLean, W. H. I., Brown, S. J., Chen, Z., Chen, Y., & Williams, H. C. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.005 · Cited by 722 · cited 1×
“Since it has been reported that the use of emollients may prevent the development of AD in high-risk infants [60,61], it might also be useful to distinguish prognostic and screening biomarkers that could identify and treat the population at risk [47].”
BackgroundNoda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428 · cited 1×
“Although excess Th2 activation characterizes both children and adults with AD, high Th9 and Th17 activation has been demonstrated in children with AD [77], while higher levels of Th22 inflammation have been found in adults with AD [78].”
BackgroundBiomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
Correlation of IL-31 serum levels with severity of atopic dermatitis
Raap, U., Wichmann, K., Bruder, M., Ständer, S., Wedi, B., Kapp, A., & Werfel, T. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.05.047 · Cited by 299
Kezic, S., O’Regan, G. M., Yau, N., Sandilands, A., Chen, H., Campbell, L. E., Kroboth, K., Watson, R., Rowland, M., Irwin McLean, W. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02540.x · Cited by 295
Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis
Furue, M., Yamamura, K., Kido‐Nakahara, M., Nakahara, T., & Fukui, Y. (2018) · Allergy · doi:10.1111/all.13239 · Cited by 240
The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype
Leung, D. Y. M., Calatroni, A., Zaramela, L. S., LeBeau, P. K., Dyjack, N., Brar, K., David, G., Johnson, K., Leung, S., Ramirez-Gama, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav2685 · Cited by 214 · cited 1×
“In addition, FLG breakdown products together with keratin 5 (KRT5), KRT14, KRT16 and AD clinical severity have been described as prognostic biomarkers for concomitant food allergy in children with AD [67].”
BackgroundEpidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy
Kim, J., Kim, B. E., Lee, J., Han, Y., Jun, H.-Y., Kim, H., Choi, J., Leung, D. Y. M., & Ahn, K. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1306 · Cited by 72
Cited by
Makowska, K., Nowaczyk, J., Blicharz, L., Waśkiel-Burnat, A., Czuwara, J., Olszewska, M., & Rudnicka, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010781 · Cited by 63
Recent advancements in the atopic dermatitis mechanism
Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902084 · Cited by 53
“Moreover, markers for predicting treatment response to specific therapies, such as serum periostin and dipeptidyl peptidase-4 (DPP-4) levels, have also been used to respond to anti-IL-13 treatment [ 153].”
BackgroundSelf-citationCLA+ memory T cells in atopic dermatitis: CLA+ T cells and atopic dermatitis
Nicolàs, L. S. S., Czarnowicki, T., Akdis, M., Pujol, R. M., Lozano‐Ojalvo, D., Leung, D. Y. M., Guttman‐Yassky, E., & Santamaria‐Babí, L. F. (2024) · Allergy · doi:10.1111/all.15816 · Cited by 25
“20,92 Over 100 different markers have been suggested as biomarkers in AD.”
Background
Metadata
- Authors
- Mastraftsi, S., Vrioni, G., Bakakis, M., Nicolaidou, E., Rigopoulos, D., Stratigos, A., & Gregoriou, S.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-08-09
- Volume
- 11
- Issue
- 16
- Pages
- 4639
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W4293680657
- Cited by
- 54
- References
- 9
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atopic Dermatitis: Striving for Reliable Biomarkers. https://app.cochat.ai/papers/10.3390/jcm11164639
- The paper
- Mastraftsi, S., Vrioni, G., Bakakis, M., Nicolaidou, E., Rigopoulos, D., Stratigos, A., & Gregoriou, S. (2022). Atopic Dermatitis: Striving for Reliable Biomarkers. Journal of Clinical Medicine. https://doi.org/10.3390/jcm11164639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.